Biomarin Pharmaceutical Inc
NASDAQ:BMRN

Watchlist Manager
Biomarin Pharmaceutical Inc Logo
Biomarin Pharmaceutical Inc
NASDAQ:BMRN
Watchlist
Price: 64.25 USD 1.26% Market Closed
Market Cap: 12.2B USD
Have any thoughts about
Biomarin Pharmaceutical Inc?
Write Note

Wall Street
Price Targets

BMRN Price Targets Summary
Biomarin Pharmaceutical Inc

Wall Street analysts forecast BMRN stock price to rise over the next 12 months.

According to Wall Street analysts, the average 1-year price target for BMRN is 99.31 USD with a low forecast of 65.65 USD and a high forecast of 133.35 USD.

Lowest
Price Target
65.65 USD
2% Upside
Average
Price Target
99.31 USD
55% Upside
Highest
Price Target
133.35 USD
108% Upside

BMRN Last Price Targets
Biomarin Pharmaceutical Inc

The latest public price target was made on Oct 30, 2024 by David Lebowitz from Citigroup , who expects BMRN stock to rise by 26% over the next 12 months. You can read more about this price target by viewing the article on StreetInsider.

Analyst Price Target Date Article
David Lebowitz
Citigroup
81 USD
Upside 26%
3 weeks ago
Oct 30, 2024
BioMarin Pharmaceutical Inc. (BMRN) PT Lowered to $81 at Citi
StreetInsider
Olivia Brayer
Cantor Fitzgerald
90 USD
Upside 40%
3 weeks ago
Oct 30, 2024
BioMarin price target lowered to $90 from $110 at Cantor Fitzgerald
TheFly
Jack Allen
Robert W. Baird
65 USD
Upside 1%
3 weeks ago
Oct 30, 2024
BioMarin Pharmaceutical Inc. (BMRN) PT Lowered to $65 at Baird
StreetInsider
Danielle Brill
Raymond James
79 USD
Upside 23%
1 month ago
Oct 10, 2024
BioMarin reinstated with an Outperform at Raymond James
TheFly
Gena Wang
Barclays
86 USD
Upside 34%
1 month ago
Oct 4, 2024
BioMarin Pharmaceutical Inc. (BMRN) PT Lowered to $86 at Barclays
StreetInsider
David Lebowitz
Citigroup
93 USD
Upside 45%
2 months ago
Sep 18, 2024
Citi Reiterates Neutral Rating on BioMarin Pharmaceutical Inc. (BMRN)
StreetInsider
Kostas Biliouris
BMO Capital
115 USD
Upside 79%
2 months ago
Sep 17, 2024
BMO Capital Reiterates BioMarin (BMRN) at Outperform: unique opportunity to buy the dip and can attract M&A interest
StreetInsider
William Pickering
Bernstein
90 USD
Upside 40%
2 months ago
Sep 17, 2024
BioMarin price target lowered to $90 from $116 at Bernstein
TheFly
George Farmer
Scotiabank
78 USD
Upside 21%
2 months ago
Sep 17, 2024
BioMarin Pharmaceutical Inc. (BMRN) PT Lowered to $78 at Scotiabank
StreetInsider
Joon Lee
Truist Financial
90 USD
Upside 40%
2 months ago
Sep 17, 2024
BioMarin Pharmaceutical Inc. (BMRN) PT Lowered to $90 at Truist Securities
StreetInsider
Gena Wang
Barclays
110 USD
Upside 71%
2 months ago
Sep 16, 2024
Barclays Reiterates Overweight Rating on BioMarin Pharmaceutical Inc. (BMRN)
StreetInsider
Christopher Raymond
Raymond James
122 USD
Upside 90%
2 months ago
Sep 5, 2024
BioMarin Pharmaceutical Inc. (BMRN) PT Raised to $122 at Piper Sandler
StreetInsider
George Farmer
Scotiabank
95 USD
Upside 48%
2 months ago
Sep 5, 2024
BioMarin Pharmaceutical Inc. (BMRN) PT Raised to $95 at Scotiabank
StreetInsider
Christopher Raymond
Raymond James
107 USD
Upside 67%
2 months ago
Aug 27, 2024
Piper Sandler Reiterates Overweight Rating on BioMarin Pharmaceutical Inc. (BMRN)
StreetInsider
Paul Matteis
Stifel Nicolaus
115 USD
Upside 79%
3 months ago
Aug 21, 2024
BioMarin price target raised to $115 from $112 at Stifel
TheFly
William Pickering
Tudor Pickering
110 USD
Upside 71%
3 months ago
Aug 20, 2024
Bernstein SocGen Group Upgrades BioMarin Pharmaceutical Inc. (BMRN) to Outperform
StreetInsider
Whitney Ijem
Canaccord Genuity
93 USD
Upside 45%
3 months ago
Aug 6, 2024
BioMarin price target raised to $93 from $89 at Canaccord
TheFly
Cory Kasimov
Evercore ISI
115 USD
Upside 79%
3 months ago
Aug 6, 2024
Biomarin Pharmaceutical Analysts Boost Their Forecasts Following Better-Than-Expected Q2 Results
Benzinga
Paul Matteis
Stifel Nicolaus
112 USD
Upside 74%
3 months ago
Aug 6, 2024
Biomarin Pharmaceutical Analysts Boost Their Forecasts Following Better-Than-Expected Q2 Results
Benzinga
Mohit Bansal
Wells Fargo
115 USD
Upside 79%
4 months ago
Jun 27, 2024
BioMarin price target raised to $115 from $111 at Wells Fargo
TheFly
William Pickering
Tudor Pickering
91 USD
Upside 42%
5 months ago
Jun 4, 2024
BridgeBio data incrementally negative for BioMarin, says Bernstein
TheFly
Jack Allen
Robert W. Baird
72 USD
Upside 12%
6 months ago
May 17, 2024
Baird Downgrades BioMarin Pharmaceutical Inc. (BMRN) to Neutral
StreetInsider
Cory Kasimov
Evercore ISI
113 USD
Upside 76%
6 months ago
May 13, 2024
BioMarin initiated with an Outperform at Evercore ISI
TheFly
George Farmer
Scotiabank
85 USD
Upside 32%
6 months ago
Apr 25, 2024
BioMarin Pharmaceutical Inc. (BMRN) PT Raised to $85 at Scotiabank
StreetInsider
Eliana Merle
UBS
119 USD
Upside 85%
7 months ago
Apr 22, 2024
UBS Reiterates Buy Rating on BioMarin Pharmaceutical Inc. (BMRN)
StreetInsider
Kostas Biliouris
BMO Capital
102 USD
Upside 59%
1 year ago
Jul 5, 2023
BMO Capital Upgrades BioMarin Pharmaceutical Inc. (BMRN) to Outperform
StreetInsider
Show More Price Targets
Show Less Price Targets
David Lebowitz
Citigroup
Price Target 81 USD
Upside/Downside 26%
View Source
Olivia Brayer
Cantor Fitzgerald
Price Target 90 USD
Upside/Downside 40%
View Source
Jack Allen
Robert W. Baird
Price Target 65 USD
Upside/Downside 1%
View Source
Danielle Brill
Raymond James
Price Target 79 USD
Upside/Downside 23%
View Source
Gena Wang
Barclays
Price Target 86 USD
Upside/Downside 34%
View Source
David Lebowitz
Citigroup
Price Target 93 USD
Upside/Downside 45%
View Source
Kostas Biliouris
BMO Capital
Price Target 115 USD
Upside/Downside 79%
View Source
William Pickering
Bernstein
Price Target 90 USD
Upside/Downside 40%
View Source
George Farmer
Scotiabank
Price Target 78 USD
Upside/Downside 21%
View Source
Joon Lee
Truist Financial
Price Target 90 USD
Upside/Downside 40%
View Source
Gena Wang
Barclays
Price Target 110 USD
Upside/Downside 71%
View Source
Christopher Raymond
Raymond James
Price Target 122 USD
Upside/Downside 90%
View Source
George Farmer
Scotiabank
Price Target 95 USD
Upside/Downside 48%
View Source
Christopher Raymond
Raymond James
Price Target 107 USD
Upside/Downside 67%
View Source
Paul Matteis
Stifel Nicolaus
Price Target 115 USD
Upside/Downside 79%
View Source
William Pickering
Tudor Pickering
Price Target 110 USD
Upside/Downside 71%
View Source
Whitney Ijem
Canaccord Genuity
Price Target 93 USD
Upside/Downside 45%
View Source
Cory Kasimov
Evercore ISI
Price Target 115 USD
Upside/Downside 79%
View Source
Paul Matteis
Stifel Nicolaus
Price Target 112 USD
Upside/Downside 74%
View Source
Mohit Bansal
Wells Fargo
Price Target 115 USD
Upside/Downside 79%
View Source
William Pickering
Tudor Pickering
Price Target 91 USD
Upside/Downside 42%
View Source
Jack Allen
Robert W. Baird
Price Target 72 USD
Upside/Downside 12%
View Source
Cory Kasimov
Evercore ISI
Price Target 113 USD
Upside/Downside 76%
View Source
George Farmer
Scotiabank
Price Target 85 USD
Upside/Downside 32%
View Source
Eliana Merle
UBS
Price Target 119 USD
Upside/Downside 85%
View Source
Kostas Biliouris
BMO Capital
Price Target 102 USD
Upside/Downside 59%
View Source
Show More Price Targets
Show Less Price Targets
Biomarin Pharmaceutical Inc Competitors:
Price Targets
OCX
OncoCyte Corp
55% Upside
VICO
Vicore Pharma Holding AB
275% Upside
RARE
Ultragenyx Pharmaceutical Inc
100% Upside
YMAB
Y-mAbs Therapeutics Inc
106% Upside
ALRN
Aileron Therapeutics Inc
414% Upside
AUPH
Aurinia Pharmaceuticals Inc
24% Upside
INCY
Incyte Corp
10% Upside
SNDX
Syndax Pharmaceuticals Inc
131% Upside

Revenue
Forecast

Revenue Estimate
Biomarin Pharmaceutical Inc

For the last 8 years the compound annual growth rate for Biomarin Pharmaceutical Inc's revenue is 13%. The projected CAGR for the next 3 years is 13%.

13%
Past Growth
13%
Estimated Growth
Estimates Accuracy
-2%
Average Miss

Operating Income
Forecast

Operating Income Estimate
Biomarin Pharmaceutical Inc

The compound annual growth rate of Biomarin Pharmaceutical Inc's operating income for the next 3 years is 88%.

N/A
Past Growth
88%
Estimated Growth
Estimates Accuracy
13%
Average Beat

Net Income
Forecast

Net Income Estimate
Biomarin Pharmaceutical Inc

The compound annual growth rate of Biomarin Pharmaceutical Inc's net income for the next 3 years is 66%.

N/A
Past Growth
66%
Estimated Growth
Estimates Accuracy
5%
Average Beat

See Also

Discover More
Why do you have more estimates than other sites?

Our estimates are sourced from the pool of sell-side and buy-side analysts that we have access to. What is available on other sites you are seeing are mostly from the sell-side analysts.

What is BMRN's stock price target?
Price Target
99.31 USD

According to Wall Street analysts, the average 1-year price target for BMRN is 99.31 USD with a low forecast of 65.65 USD and a high forecast of 133.35 USD.

What is Biomarin Pharmaceutical Inc's Revenue forecast?
Projected CAGR
13%

For the last 8 years the compound annual growth rate for Biomarin Pharmaceutical Inc's revenue is 13%. The projected CAGR for the next 3 years is 13%.

What is Biomarin Pharmaceutical Inc's Operating Income forecast?
Projected CAGR
88%

The compound annual growth rate of Biomarin Pharmaceutical Inc's operating income for the next 3 years is 88%.

What is Biomarin Pharmaceutical Inc's Net Income forecast?
Projected CAGR
66%

The compound annual growth rate of Biomarin Pharmaceutical Inc's net income for the next 3 years is 66%.

Back to Top